Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on May 8, 2012
At a panel discussion titled: "Policies and technologies needed to rein in 'designer drugs'", hosted by RTI International, SSDP Associate Director, Stacia Cosner, asks the panelists about the potential benefits of a regulation and control approach to the issue as opposed to a criminalization approach. "Designer drugs" are referring to substances such as synthetic cannabinoids like K2, or "spice", bath salts, etc.